PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism

• Main Authors: Mingming Sun (Author), Leilei Li (Author), Yujia Niu (Author), Yingzhi Wang (Author), Qi Yan (Author), Fei Xie (Author), Yaya Qiao (Author), Jiaqi Song (Author), Huanran Sun (Author), Zhen Li (Author), Sizhen Lai (Author), Hongkai Chang (Author), Han Zhang (Author), Jiyan Wang (Author), Chenxin Yang (Author), Huifang Zhao (Author), Junzhen Tan (Author), Yanping Li (Author), Shuangping Liu (Author), Bin Lu (Author), Min Liu (Author), Guangyao Kong (Author), Yujun Zhao (Author), Chunze Zhang (Author), Shu-Hai Lin (Author), Cheng Luo (Author), Shuai Zhang (Author), Changliang Shan (Author)
• Format: Book
• Published: Elsevier, 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Metabolic reprogramming is a hallmark of cancer, including lung cancer. However, the exact underlying mechanism and therapeutic potential are largely unknown. Here we report that protein arginine methyltransferase 6 (PRMT6) is highly expressed in lung cancer and is required for cell metabolism, tumo...